EGFR and non-small cell lung carcinoma: Furthermore, given the high proportion of multiple small BMs in EGFR‐mutated NSCLC patients, which leads to intracranial disease assessment difficulties, modified RESCIST 1.111 was applied to evaluate the CNS response to dacomitinib.